Search

Your search keyword '"Lazar, Alexander J"' showing total 2,209 results

Search Constraints

Start Over You searched for: Author "Lazar, Alexander J" Remove constraint Author: "Lazar, Alexander J"
2,209 results on '"Lazar, Alexander J"'

Search Results

3. ASO Visual Abstract: Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas)—Single-Institution Study of 95 Surgical Patients

4. ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97

5. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma

6. International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease

8. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions

9. Analysis of germline-driven ancestry-associated gene expression in cancers

10. Epigenomic and Transcriptomic Profiling of Solitary Fibrous Tumors Identifies Site-Specific Patterns and Candidate Genes Regulated by DNA Methylation

12. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748

13. The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms

15. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

16. BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms

17. Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee

18. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells

19. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

20. Comprehensive proteogenomic characterization of rare kidney tumors

23. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

24. Analytical protocol to identify local ancestry-associated molecular features in cancer

25. Pan-cancer proteogenomics characterization of tumor immunity

27. Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma

28. Deep learning integrates histopathology and proteogenomics at a pan-cancer level

29. Proteogenomic insights suggest druggable pathways in endometrial carcinoma

30. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

31. Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma

34. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation

35. Pan-cancer proteogenomics connects oncogenic drivers to functional states

36. Proteogenomic data and resources for pan-cancer analysis

37. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers.

38. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer

39. Pan-cancer analysis of whole genomes

40. B cells and tertiary lymphoid structures promote immunotherapy response

41. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

42. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

43. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor

44. Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma

45. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

48. Multi-modal molecular programs regulate melanoma cell state

50. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma

Catalog

Books, media, physical & digital resources